Medical treatment of dystonia

Movement Disorders

Volumn 28, Issue 7, 2013, Pages 1001-1012

  Jankovic, Joseph ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Baclofen; Botulinum toxin; Dystonia; Tetrabenazine; Trihexyphenidyl

Indexed keywords

'SALIX'; 5 HYDROXYTRYPTOPHAN; ACETYL HEXAPEPTIDE 8; ADX 48261; AMPICILLIN; BACLOFEN; BOTULINUM TOXIN; BOTULINUM TOXIN A; BOTULINUM TOXIN B; CANNABINOID 1 RECEPTOR AGONIST; CARBIDOPA PLUS LEVODOPA; CENTRAL NERVOUS SYSTEM AGENTS; CEVIMELINE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CLONAZEPAM; CLOZAPINE; DEFERIPRONE; DIAZEPAM; DIPHENHYDRAMINE; DIPRAGLURANT; DOPAMINE RECEPTOR BLOCKING AGENT; DRONABINOL; GLANDOSANE; LEVODOPA; LORAZEPAM; MAVOLURANT; OCTAHYDRO 4 HYDROXY 4 [(3 METHYLPHENYL)ETHYNYL] 1H INDOLE 1 CARBOXYLIC ACID METHYL ESTER; PILOCARPINE; SALIVART; TETRABENAZINE; TETRAHYDROBIOPTERIN; TRIHEXYPHENIDYL; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZONISAMIDE;

ACUTE DYSTONIC REACTION; AGRANULOCYTOSIS; AKATHISIA; ALLERGIC REACTION; ANTICHOLINERGIC SYNDROME; BLEPHAROSPASM; BLURRED VISION; BRAIN DEPTH STIMULATION; CATHETER COMPLICATION; CERVICAL DYSTONIA; COGNITIVE DEFECT; CONFUSION; CONSTIPATION; DEPRESSION; DIPLOPIA; DOPAMINE RESPONSIVE DYSTONIA; DOSE RESPONSE; DROWSINESS; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SAFETY; DRY EYE; DYSKINESIA; DYSPHAGIA; DYSTONIA; EARLY ONSET DYSTONIA; EVIDENCE BASED MEDICINE; EYE DISEASE; FEVER; FLU LIKE SYNDROME; FOCAL DYSTONIA; GENERALIZED DYSTONIA; HEMATOMA; HOARSENESS; HUMAN; INSOMNIA; LOW DRUG DOSE; MALAISE; MEMORY DISORDER; MOTOR DYSFUNCTION; MUSCLE WEAKNESS; MYOCLONUS DYSTONIA; NECK PAIN; NEUROLOGIC DISEASE; OROMANDIBULAR DYSTONIA; PHYSIOTHERAPY; PRIORITY JOURNAL; PTOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RAPID ONSET DYSTONIA PARKINSONISM; RASH; REVIEW; SEDATION; SEGMENTAL DYSTONIA; SIDE EFFECT; SPASMODIC DYSPHONIA; SPEECH DISORDER; TARDIVE DYSKINESIA; TARDIVE DYSTONIA; TRANSIENT BREATHY HYPOPHONIA; TREATMENT OUTCOME; TREATMENT RESPONSE; URINE RETENTION; WRITER'S CRAMP; XEROSTOMIA;

EID: 84880815904     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.25552     Document Type: Review

References (114)

1. Jankovic J. Treatment of dystonia. Lancet Neurol 2006;5:864-872.
2. Jankovic J. Treatment of hyperkinetic movement disorders. Lancet Neurol 2009;8:844-856.
3. Waln O, Jankovic J. Bilateral globus pallidus internus deep brain stimulation after bilateral pallidotomy in a patient with generalized early-onset primary dystonia. Mov Disord 2013 Apr 11. [Epub ahead of print].
4. Volkmann J, Wolters A, Kupsch A, et al. Pallidal deep brain stimulation in patients with primary generalised or segmental dystonia: 5-year follow-up of a randomised trial. Lancet Neurol 2012;11:1029-1038.
5. Walsh RA, Sidiropoulos C, Lozano AM, et al. Bilateral pallidal stimulation in cervical dystonia: blinded evidence of benefit beyond 5 years. Brain 2013;136(Pt 3):761-769.
6. Svetel M, Kozic D, Stefanoval E, et al. Dystonia in Wilson's disease. Mov Disord 2001;16:719-723.
7. Delnooz CC, Horstink MW, Tijssen MA, van de Warrenburg BP. Paramedical treatment in primary dystonia: a systematic review. Mov Disord. 2009;24:2187-2198.
8. Abbruzzese G, Berardelli A. Sensorimotor integration in movement disorders. Mov Disord 2003:18:231-240.
9. Tas N, Karatas K, Sepici V. Hand orthosis as a writing aid in writer's cramp. Mov Disord 2001;16:1185-1189.
10. Zeuner KE, Peller M, Knutzen A, et al. Motor re-training does not need to be task specific to improve writer's cramp. Mov Disord 2008;23:2319-2327.
11. Jankovic J. Peripherally-induced movement disorders. Neurol Clin 2009;27:821-832.
12. Berque P, Gray H, McFadyen A. A combination of constraint-induced therapy and motor control retraining in the treatment of focal hand dystonia in musicians: a long-term follow-up study. Med Probl Perform Art 2013;28:33-46.
13. Zeuner KE, Hallett M. Sensory training as treatment for focal hand dystonia: a 1-year follow-up. Mov Disord 2003;18:1044-1047.
14. Byl NN, Nagajaran S, McKenzie AL. Effect of sensory discrimination training on structure and function in patients with focal hand dystonia: a case series. Arch Phys Med Rehab 2003;84:1505-1514.
15. Wu AD, Fregni F, Simon DK, Deblieck C, Pascual-Leone A. Noninvasive brain stimulation for Parkinson's disease and dystonia. Neurotherapeutics 2008;5:345-361.
16. Tinazzi M, Farina S, Bhatia K, et al. TENS for the treatment of writer's cramp dystonia: a randomized, placebo-controlled study. Neurology 2005;64:1946-1948.
17. Rosengren SM, Colebatch JG. Cervical dystonia responsive to acoustic and galvanic vestibular stimulation. Mov Disord 2006;21:1495-1499.
18. Steinberger D, Korinthenberg R, Topka H, et al. Dopa-responsive dystonia: mutation analysis of GCH1 and analysis of therapeutic doses of L-dopa. German Dystonia Study Group. Neurology 2000;55:1735-1737.
19. Yaltho TC, Jankovic J, Lotze T. The association of Tourette syndrome and dopa-responsive dystonia. Mov Disord 2011;26:359-360.
20. Trender-Gerhard I, Sweeney MG, Schwingenschuh P, et al. Autosomal-dominant GTPCH1-deficient DRD: clinical characteristics and long-term outcome of 34 patients. J Neurol Neurosurg Psychiatry 2009;80:839-845.
21. Schneider SA, Mohire MD, Trender-Gerhard I, et al. Neurology 2006;66:599-601.
22. Clot F, Grabli D, Cazeneuve C, et al.; French Dystonia Network. Exhaustive analysis of BH4 and dopamine biosynthesis genes in patients with dopa-responsive dystonia. Brain 2009;132:1753-1763.
23. Friedman J, Roze E, Abdenur JE, et al. Sepiapterin reductase deficiency: a treatable mimic of cerebral palsy. Ann Neurol 2012;71:520-530.
24. Bainbridge MN, Wiszniewski W, Murdock DR, et al. Whole-genome sequencing for optimized patient management. Sci Transl Med. 2011;3:87re3.
25. Hwang WJ, Calne DB, Tsui JK, de la Fuente-Fernandez R. The long-term response to levodopa in dopa-responsive dystonia. Parkinsonism Relat. Disord 2001;8:1-5.
26. Calderon DP, Fremont R, Kraenzlin F, Khodakhah K. The neural substrates of rapid-onset dystonia-parkinsonism. Nat Neurosci 2011;14:357-365.
27. Brashear A, Cook JF, Hill DF, et al. Psychiatric disorders in rapid-onset dystonia-parkinsonism. Neurology 2012;79:1168-1173.
28. Karp BI, Goldstein SR, Chen R, et al. An open trial of clozapine for dystonia. Mov Disord 1999;14:652-657.
29. Jankovic J, Clarence-Smith K. Tetrabenazine for the treatment of chorea and other hyperkinetic movement disorders. Expert Rev Neurother 2011;11:1509-1523.
30. Jimenez-Shahed J, Jankovic J. Tetrabenazine for treatment of chorea associated with Huntington's disease. Expert Opin Orphan Drugs 2013 (in press).
31. Burke RE, Fahn S, Marsden CD. Torsion dystonia: a double-blind, prospective trial of high-dosage trihexyphenidyl. Neurology 1986;36:160-164.
32. Taylor AE, Lang AE, Saint-Cyr JA, et al. Cognitive processes in idiopathic dystonia treated with high-dose anticholinergic therapy: Implications for treatment strategies. Clin Neuropharmacol 1991;14:62-77.
33. Truong DD, Sandromi P, van der Noort S, Matsumoto RR. Diphenhydramine is effective in the treatment of idiopathic dystonia. Arch Neurol 1995;52:405-407.
34. Benarroch EE. GABAB receptors: structure, functions, and clinical implications. Neurology 2012;78:578-584.
35. Narayan RK, Loubser PG, Jankovic J, et al. Intrathecal baclofen for intractable axial dystonia. Neurology 1991;41:1141-1142.
36. Hou JG, Ondo W, Jankovic J. Intrathecal baclofen for dystonia. Mov Disord 2001;16:1201-1202.
37. Albright AL, Barry MJ, Shafron DH, Ferson SF. Intrathecal baclofen for generalized dystonia. Dev Med Child Neurol 2001;43:652-657.
38. van Hilten BJ, van de Beek WJ, Hoff JI, et al. Intrathecal baclofen for the treatment of dystonia in patients with reflex sympathetic dystrophy. N Engl J Med 2000;343:625-630.
39. Dressler D, Bigalke H, Benecke R. Botulinum toxin type B in antibody-induced botulinum toxin type a therapy failure. J Neurol 2003;250:967-969.
40. Bardutzky J, Tronnier V, Schwab S, Meinck HM. Intrathecal baclofen for stiff-person syndrome: life-threatening intermittent catheter leakage. Neurology 2003;60:1976-1978.
41. Frucht SJ, Bordelon Y, Houghton WH, Reardam D. A pilot tolerability and efficacy trial of sodium oxybate in ethanol-responsive movement disorders. Mov Disord 2005;20:1330-1337.
42. Miyazaki Y, Sako W, Asanuma K, et al. Efficacy of zolpidem for dystonia: a study among different subtypes. Front Neurol. 2012;3:58.
43. Waln O. Jankovic J. Zolpidem improves tardive dyskinesia and akathisia. Mov Disord (in press). [Epub 2013 May 1. DOI: 10.1002/mds.25480]
44. Kaji R, Kohara N, Katayama M, et al. Muscle afferent block by intramuscular injection of lidocaine for the treatment of writer's cramp. Muscle Nerve 1995;18:234-235.
45. Yoshida K, Kaji R, Kubori T, et al. Muscle afferent block for the treatment of oromandibular dystonia. Mov Disord 1998;13:699-695.
46. Ohara S, Hayashi R, Momoi H, et al. Mexiletine in the treatment of spasmodic torticollis. Mov Disord 1998;13:934-940.
47. Lucetti C, Nuti A, Gambaccini G, et al. Mexiletine in the treatment of torticollis and generalized dystonia. Clin Neuropharmacol 2000;23:186-189.
48. Massey JM. Treatment of spasmodic torticollis with intramuscular phenol injection. J Neurol Neurosurg Psychiatry 1995;58:258-259.
49. Bhatia KP. Paroxysmal dyskinesias. Mov Disord 2011;26:1157-1165.
50. Opal P, Tintner R, Jankovic J, et al. Intrafamilial phenotypic variability of the DYT1 dystonia: From asymptomatic TOR1A gene carrier status to dystonic storm. Mov Disord 2002;17:339-345.
51. Mariotti P, Fasano A, Contarino MF, et al. Management of status dystonicus: our experience and review of the literature. Mov Disord 2007;22:963-968.
52. Fasano A, Ricciardi L, Bentivoglio AR, et al. Status dystonicus: predictors of outcome and progression patterns of underlying disease. Mov Disord. 2012;27:783-788.
53. Jech R, Bares M, Urgosík D, et al. Deep brain stimulation in acute management of status dystonicus. Mov Disord 2009;24:2291-2292.
54. Krauss JK, Akeyson EW, Giam P, Jankovic J. Propofol-induced dyskinesias in Parkinson's disease. Anesth Analg 1996;83:420-422.
55. Jankovic J, Albanese A, Atassi MZ, Dolly JO, Hallett M, Mayer N, eds. Botulinum toxin: Therapeutic clinical practice and science. Philadelphia, PA: Saunders (Elsevier); 2009:1-492.
56. Jankovic J, Orman J. Botulinum A toxin for cranial-cervical dystonia: a double-blind, placebo-controlled study. Neurology 1987;37:616-623.
57. Albanese A. Terminology for preparations of botulinum neurotoxins: what a difference a name makes. JAMA 2011;305:89-90.
58. Thenganatt MA, Fahn S. Botulinum toxin for the treatment of movement disorders. Curr Neurol Neurosci Rep 2012;12:399-409.
59. Scott AB, Rosenbaum A, Collins CC. Pharmacologic weakening of extraocular muscles. Invest Ophthalmol Vis Sci 1973;12:924-927.
60. Colosimo C, Tiple D, Berardelli A. Efficacy and safety of long-term botulinum toxin treatment in craniocervical dystonia: a systematic review. Neurotox Res 2012;22:265-273.
61. Jankovic J, Kenney C, Grafe S, Goertelmeyer R, Comes G. Relationship between various clinical outcome assessments in patients with blepharospasm. Mov Disord 2009;24:407-413.
62. Jankovic J, Comella C, Hanschmann A, Grafe S. Efficacy and safety of incobotulinumtoxinA (NT 201, Xeomin) in the treatment of blepharospasm-a randomized trial. Mov Disord 2011;26:1521-1528.
63. Truong D, Comella C, Fernandez HH, Ondo WG; Dysport Benign Essential Blepharospasm Study Group. Efficacy and safety of purified botulinum toxin type A (Dysport) for the treatment of benign essential blepharospasm: a randomized, placebo-controlled, phase II trial. Parkinsonism Relat Disord 2008;14:407-414.
64. Jankovic J. Pretarsal injection of botulinum toxin for blepharospasm and apraxia of eyelid opening. J Neurol Neurosurg Psychiatry 1996;60:704.
65. Yaltho TC, Jankovic J. The many faces of hemifacial spasm: differential diagnosis of unilateral facial spasms. Mov Disord 2011;26:1582-1592.
66. Charous SJ, Comella CL, Fan W. Jaw-opening dystonia: quality of life after botulinum toxin injections. Ear Nose Throat J 2011;90:E9-E12.
67. Long H, Liao Z, Wang Y, Liao L, Lai W. Efficacy of botulinum toxins on bruxism: an evidence-based review. Int Dent J 2012;62:1-5.
68. Tan E-K, Jankovic J. Treating severe bruxism with botulinum toxin. J Am Dent Assoc 2000;131:211-216.
69. Fulmer SL, Merati AL, Blumin JH. Efficacy of laryngeal botulinum toxin injection: comparison of two techniques. Laryngoscope 2011;121:1924-1928.
70. Collins A, Jankovic J. Botulinum toxin injection for congenital muscular torticollis presenting in children and adults. Neurology 2006;67:1083-1085.
71. Truong D, Duane DD, Jankovic J, et al. Efficacy and safety of botulinum type A toxin (Dysport) in cervical dystonia: results of the first US randomized, double-blind, placebo-controlled study. Mov Disord 2005;20:783-791.
72. Brashear A, Lew MF, Dykstra DD, et al. Safety and efficacy of Neurobloc (botulinum toxin type B) in type A-responsive cervical dystonia. Neurology 1999;53:1439-1446.
73. Brin MF, Comella CL, Jankovic J, Lai F, Naumann M; CD-017 BoNTA Study Group. Long-term treatment with botulinum toxin type A in cervical dystonia has low immunogenicity by mouse protection assay. Mov Disord 2008;23:1353-1360.
74. Charles D, Brashear A, Hauser RA, et al. Efficacy, tolerability, and immunogenicity of onabotulinumtoxina in a randomized, double-blind, placebo-controlled trial for cervical dystonia. Clin Neuropharmacol. 2012;35:208-214.
75. Fernandez HH, Pappert EJ, Comella CL, et al. Efficacy and safety of incobotulinumtoxinA in subjects previously treated with botulinum toxin versus toxin-naïve subjects with cervical dystonia. Tremor Other Hyperkinet Mov 2013;3. Available at: http://tremorjournal.org/article/view/140. Accessed May 15, 2013.
76. Nijmeijer SW, Koelman JH, Kamphuis DJ, Tijssen MA. Muscle selection for treatment of cervical dystonia with botulinum toxin-a systematic review. Parkinsonism Relat Disord 2012;18:731-736.
77. Jankovic J, Adler CH, Charles PD, et al. Rationale and design of a prospective study: cervical dystonia patient registry for observation of onabotulinumtoxinA efficacy (CD PROBE). BMC Neurol 2011;11:140.
78. Ramirez-Castaneda J, Jankovic J. Long-term efficacy and safety of botulinum toxin injections in dystonia. Toxins (Basel) 2013;5:249-266.
79. Jankovic J. Disease-oriented approach to botulinum toxin use. Toxicon 2009;54:614-623.
80. Jankovic J. Camptocormia, head drop and other bent spine syndromes: heterogeneous etiology and pathogenesis of parkinsonian deformities. Mov Disord 2010;25:527-528.
81. Tassorelli C, Furnari A, Buscone S, et al. Pisa syndrome in Parkinson's disease: clinical, electromyographic, and radiological characterization. Mov Disord 2012;27:227-235.
82. Lungu C, Karp BI, Alter K, Zolbrod R, Hallett M. Long-term follow-up of botulinum toxin therapy for focal hand dystonia: outcome at 10 years or more. Mov Disord. 2011;26:750-753.
83. Dhungana S, Jankovic J. Yips and other movement disorders in golfers. Mov Disord 2013;28:576-581.
84. Schuele S, Jabusch HC, Lederman RJ, Altenmuller E. Botulinum toxin injections in the treatment of musician's dystonia. Neurology 2005;64:341-343.
85. Sitburana O, Jankovic J. Focal hand dystonia, mirror dystonia and motor overflow. J Neurol Sci 2008;266:31-33.
86. Bentivoglio AR, Ialongo T, Bove F, De Nigris F, Fasano A. Retrospective evaluation of the dose equivalence of Botox(®) and Dysport (®) in the management of blepharospasm and hemifacial spasm: a novel paradigm for a never ending story. Neurol Sci 2012;33:261-267.
87. Hallett M, Albanese A, Dressler D, et al. Evidence-based review and assessment of botulinum neurotoxin for the treatment of movement disorders. Toxicon 2013;67:94-114.
88. Baizabal-Carvallo JF, Jankovic J, Feld J. Flu-like symptoms and associated immunological response following therapy with botulinum toxins. Neurotox Res 2013 May 16. [Epub ahead of print].
89. Jankovic J, Vuong KD, Ahsan J. Comparison of efficacy and immunogenicity of original versus current botulinum toxin in cervical dystonia. Neurology 2003;60:1186-1188.
90. Comella CL, Jankovic J, Shannon KM, et al.; Dystonia Study Group. Comparison of botulinum toxin serotypes A and B for the treatment of cervical dystonia. Neurology 2005;65:1423-1429.
91. Tintner R, Gross R, Winzer UF, Smalky KA, Jankovic J. Autonomic function after botulinum toxin type A or B: a double-blind, randomized trial. Neurology 2005;65:765-767.
92. Jankovic J, Hunter C, Dolimbek BZ, et al. Clinico-immunologic aspects of botulinum toxin type B treatment of cervical dystonia. Neurology 2006;67:2233-2235.
93. Chinnapongse R, Gullo K, Nemeth P, Zhang Y, Griggs L. Safety and efficacy of botulinum toxin type B for treatment of sialorrhea in Parkinson's disease: a prospective double-blind trial. Mov Disord 2012;27:219-226.
94. Benecke R. Clinical relevance of botulinum toxin immunogenicity. BioDrugs 2012;26:e1-e9.
95. Sethi KD, Rodriguez R, Olayinka B. Satisfaction with botulinum toxin treatment: a cross-sectional survey of patients with cervical dystonia. J Med Econ 2012;15:419-423.
96. Simpson DM, Blitzer A, Brashear A, et al.; Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Assessment: botulinum neurotoxin for the treatment of movement disorders (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2008;70:1699-1706.
97. Wabbels B, Reichel G, Fulford-Smith A, Wright N, Roggenkamper P. Double-blind, randomised, parallel group pilot study comparing two botulinum toxin type A products for the treatment of blepharospasm. J Neural Transm 2011;118:233-239.
98. Hanna PA, Jankovic J. Mouse bioassay versus Western blot assay for botulinum toxin antibodies: correlation with clinical response. Neurology 1998;50:1624-1629.
99. Hanna PA, Jankovic J, Vincent A. Comparison of mouse bioassay and immunoprecipitation assay for botulinum toxin antibodies. J Neurol Neurosurg Psychiatry 1999;66:612-616.
100. Burbaud P, Ducerf C, Cugy E, et al. Botulinum toxin treatment in neurological practice: how much does it really cost? A prospective cost-effectiveness study. J Neurol 2011;258:1670-1675.
101. Thompson VB, Jinnah HA, Hess EJ. Convergent mechanisms in etiologically-diverse dystonias. Expert Opin Ther Targets 2011;15:1387-1403.
102. Zadikoff C, Wadia PM, Miyasaki J, et al. Cannabinoid, CB1 agonists in cervical dystonia: failure in a phase IIa randomized controlled trial. Basal Ganglia 2011;1:91-95.
103. Berg D, Godau J, Trenkwalder C, et al. AFQ056 treatment of levodopa-induced dyskinesias: results of 2 randomized controlled trials. Mov Disord 2011;26:1243-1250.
104. Dickerson JW, Conn PJ. Therapeutic potential of targeting metabotropic glutamate receptors for Parkinson's disease. Neurodegener Dis Manag 2012;2:221-232.
105. Poewe W, Mahlknecht P, Jankovic J. Emerging therapies for Parkinson's disease. Curr Opin Neurol 2012;25:448-459.
106. Koshy JC, Sharabi SE, Feldman EM, Hollier LH Jr, Patrinely JR, Soparkar CN. Effect of dietary zinc and phytase supplementation on botulinum toxin treatments. J Drugs Dermatol 2012;11:507-512.
107. Lungu C, Considine E, Zahir S, Ponsati B, Arrastia S, Hallett M. Pilot study of topical acetyl hexapeptide-8 in the treatment for blepharospasm in patients receiving botulinum toxin therapy. Eur J Neurol 2013;20:515-518.
108. Park TY, Shin MJ, Park SD, Lee SK. Alleviation of abnormal synaptic neurotransmitter release by cell-permeable form of the truncated SNAP-25 upon transcutaneous delivery. Neurosci Lett 2013;543:52-57.
109. Zorzi G, Zibordi F, Chiapparini L, et al. Iron-related MRI images in patients with pantothenate kinase-associated neurodegeneration (PKAN) treated with deferiprone: results of a phase II pilot trial. Mov Disord 2011;26:1756-1759.
110. Hou JG, Jankovic J. Movement disorders in Friedreich's ataxia. J Neurol Sci 2003;206:59-64.
111. Velasco-Sánchez D, Aracil A, Montero R, et al. Combined therapy with idebenone and deferiprone in patients with Friedreich's ataxia. Cerebellum 2011;10:1-8.
112. Li X, Jankovic J, Le W. Iron chelation and neuroprotection in neurodegenerative diseases. J Neural Transm 2011;118:473-477.
113. Dusek P, Jankovic J, Le W. Iron dysregulation in movement disorders. Neurobiol Dis 2012;46:1-18.
114. Schneider SA, Dusek P, Hardy J, Westenberger A, Jankovic J, Bhatia KP. Genetics and pathophysiology of neurodegeneration with brain iron accumulation (NBIA). Curr Neuropharmacol 2013;11:59-79.